Novartis plans BTK inhibitor filing in chronic spontaneous urticaria as Celldex’s mid-stage data excite investors
Novartis unveiled positive registrational data for its BTK inhibitor candidate in chronic spontaneous urticaria, triggering plans for regulatory filings.
But strong Phase II readout from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.